Anja Möricke

Humboldt-Universität zu Berlin — Germany

Medicine · Health Sciences

42h-index8.9kcitations173works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(151), Childhood Cancer Survivors' Quality of Life(69), Acute Myeloid Leukemia Research(37), Chronic Myeloid Leukemia Treatments(35), Chronic Lymphocytic Leukemia Research(21)

Publications173 total

Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow niche
Cancer Letters·2026Open Access
Demographic modelling of haemoglobinopathies incidence in Germany: A call for targeted public health policy responses
2026Open Access
Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
Leukemia·2025Open Access
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009
Journal of Clinical Oncology·2025
Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
HemaSphere·2025· 1 citedOpen Access
Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia
Universität Zürich, ZORA·2025Open Access
Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation
Haematologica·2025· 3 citedOpen Access
A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
Blood·2024· 2 cited
Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
Blood·2024
Auer rod‐positive acute leukemia with predominantly lymphoid immunophenotype: Report on 11 cases and review of literature
Pediatric Blood & Cancer·2024Open Access
Severe steroid‐related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy—An observational Ponte di Legno Toxicity Working Group Study
British Journal of Haematology·2024· 1 citedOpen Access
<i>Pneumocystis jirovecii</i> pneumonia in paediatric acute lymphoblastic leukaemia: A report from the <scp>multi‐international</scp> clinical trial <scp>AIEOP‐BFM ALL</scp> 2009
British Journal of Haematology·2024· 5 citedOpen Access
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study
Leukemia·2024· 7 citedOpen Access
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
Blood·2024· 11 cited
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
Journal of Clinical Oncology·2023· 13 cited
Deciphering the molecular complexity of the IKZF1&lt;sup&gt;plus&lt;/sup&gt; genomic profile using Optical Genome Mapping
Haematologica·2023· 3 citedOpen Access
In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study
Blood·2023· 2 cited
Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017
Blood·2023· 12 cited
P322: DECIPHERING THE UNDERLYING MOLECULAR COMPLEXITY OF THE IKZF1PLUS SIGNATURE
HemaSphere·2023Open Access
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
HemaSphere·2023· 14 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Martin Schrappe(37), Martin Stanulla(23), Martin Zimmermann(13), Gunnar Cario(13), Andishe Attarbaschi(12), Giovanni Cazzaniga(11), André Schrauder(10), Georg Mann(10), Claus R. Bartram(9), Maria Grazia Valsecchi(9), Giuseppe Basso(9), Felix Niggli(9), Jochen Harbott(9), Valentino Conter(8), Franco Locatelli(8), Andrea Biondi(8), Alfred Reiter(8), Karl Welte(8), Gabriele Escherich(8), Renate Panzer‐Grümayer(7)